64670-14-0

Usage

Uses

Used in Organic Synthesis:
BETA-OXO-CYCLOPENTANEPROPANOIC ACID METHYL ESTER is used as a building block for the synthesis of various organic compounds due to its cyclopentane ring and carbonyl group.
Used in Pharmaceutical Research:
In the pharmaceutical industry, BETA-OXO-CYCLOPENTANEPROPANOIC ACID METHYL ESTER is used as a key intermediate for the development of pharmaceutical products and fine chemicals. Its unique structure and functional groups make it a valuable component in the synthesis of new drug candidates.

Upstream product

• 67-56-1 methanol 
• 134302-12-8 5-(cyclopentanecarbonyl)2,2-dimethyl-1,3-dioxane-4,6-dione 
• 105-45-3 acetoacetic acid methyl ester 
• 4524-93-0 Cyclopentanecarboxylic acid chloride 
• 2033-24-1 cycl-isopropylidene malonate 
• 64670-06-0 methyl (+/-)-8-bromo-3-oxooctanoate 
• 412018-99-6 2-cyclopentanecarbonyl-3-oxo-butyric acid ethyl ester 

Downstream Products

• 199863-76-8 2-amino-6-cyclopentyl-4(1H)-pyrimidinone 
• 1292289-62-3 methyl 4-cyclopentyl-2-(methylsulfonyl)pyrimidine-5-carboxylate 

Relevant academic research and scientific papers

NEW ANALOGS AS ANDROGEN RECEPTOR AND GLUCOCORTICOID RECEPTOR MODULATORS

The present invention relates to novel dihydropyridine derivatives of formula (I): as modulators of nuclear receptors selected from androgen receptor and glucocorticoid receptor, to processes for their preparation, to pharmaceutical compositions comprising said compounds and to the use of said for manufacturing a medicament for the treatment of pathological conditions or diseases that can improve by modulation of androgen receptor and/or glucocorticoid receptor, selected from cancer, metastasizing cancers, benign prostate hyperplasia, polycystic ovary syndrome (PCOS), hair loss, hirsutism, acne, hypogonadism, muscle wasting diseases, cachexia, Cushing's syndrome, anti-psychotic drug induced weight gain, obesity, post-traumatic stress disorder and alcoholism.

CHEMICAL COMPOUNDS

The invention is directed to to substituted indazole derivatives. Specifically, the invention is directed to compounds according to Formula I: wherein R1 - R6 and X are defined herein. The compounds of the invention are inhibitors of PDK1 and can be useful in the treatment of disorders characterized by constitutively activated ACG kinases such as cancer and more specifically leukemia and cancers of the breast, colon, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PDK1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Structure-activity relationship study of [1,2,3]thiadiazole necroptosis inhibitors

Necroptosis is a regulated caspase-independent cell death mechanism that results in morphological features resembling non-regulated necrosis. This form of cell death can be induced in an array of cell types in apoptotic deficient conditions with death receptor family ligands. A series of [1,2,3]thiadiazole benzylamides was found to be potent necroptosis inhibitors (called necrostatins). A structure-activity relationship study revealed that small cyclic alkyl groups (i.e. cyclopropyl) and 2,6-dihalobenzylamides at the 4- and 5-positions of the [1,2,3]thiadiazole, respectively, were optimal. In addition, when a small alkyl group (i.e. methyl) was present on the benzylic position all the necroptosis inhibitory activity resided with the (S)-enantiomer. Finally, replacement of the [1,2,3]thiadiazole with a variety of thiophene derivatives was tolerated, although some erosion of potency was observed.

Ketone derivatives and medical application thereof

The present invention relates to ketone derivatives represented by the following formula and medical agents containing the ketone derivatives or pharmacologically acceptable salts thereof as an active ingredient, and in particular, relates to a hematopoietic agent; it is shown that the present invention increases blood cells, such as platelets, white blood cells, and red blood cells, and is effective in preventing and treating cytopenia caused by cancer chemotherapy, radiation therapy, and the like.